Expert Opinion on Biological Therapy, Volume 20, Issue 8 (2020)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Biological Therapy, Volume 20, Issue 8 (2020)

See all volumes and issues
Vol 24, 2024 Vol 23, 2023 Vol 22, 2022 Vol 21, 2021 Volume 20, 2020 Vol 19, 2019 Vol 18, 2018 Vol 17, 2017 Vol 16, 2016 Vol 15, 2015 Vol 14, 2014 Vol 13, 2013 Vol 12, 2012 Vol 11, 2011 Vol 10, 2010 Vol 9, 2009 Vol 8, 2008 Vol 7, 2007 Vol 6, 2006 Vol 5, 2005 Vol 4, 2004 Vol 3, 2003 Vol 2, 2002 Vol 1, 2001
Download citations Download PDFs Download issue

Letter to the Editor

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era
Marco Galluzzo, Lorenzo Tofani, Luca Bianchi & Marina Talamonti
Pages: 829-830
Published online: 16 Jun 2020
AbstractforStatus of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era | Full Text | References | PDF (143.3 KB) | EPUB
  • 2758 Views
  • 12 CrossRef citations
  • 0Altmetric

Editorial

Editorial
Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?
Leticia Moreno-Fierros, Ileana García-Silva & Sergio Rosales-Mendoza
Pages: 831-836
Published online: 26 May 2020
First Page PreviewforDevelopment of SARS-CoV-2 vaccines: should we focus on mucosal immunity? | Full Text | References | PDF (613.3 KB) | EPUB
  • 9746 Views
  • 52 CrossRef citations
  • 0Altmetric
Free Access
Editorial
From observational studies to personalized treatment in spondylarthritis: focus on IL-17 inhibition
Daniel Wendling & Philippe Goupille
Pages: 837-840
Published online: 17 Jun 2020
First Page PreviewforFrom observational studies to personalized treatment in spondylarthritis: focus on IL-17 inhibition | Full Text | References | PDF (150.3 KB) | EPUB
  • 891 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug Evaluation

Article
Guselkumab for the treatment of palmoplantar pustulosis
Masamoto Murakami
Pages: 841-852
Published online: 12 May 2020
AbstractforGuselkumab for the treatment of palmoplantar pustulosis | Full Text | References | PDF (1.5 MB) | EPUB
  • 916 Views
  • 9 CrossRef citations
  • 0Altmetric
Article
Ligelizumab for the treatment of chronic spontaneous urticaria
Bettina Wedi
Pages: 853-861
Published online: 19 May 2020
AbstractforLigelizumab for the treatment of chronic spontaneous urticaria | Full Text | References | PDF (928 KB) | EPUB
  • 622 Views
  • 8 CrossRef citations
  • 0Altmetric
Article
Toripalimab for the treatment of melanoma
Bixia Tang, Zhihong Chi & Jun Guo
Pages: 863-869
Published online: 14 May 2020
AbstractforToripalimab for the treatment of melanoma | Full Text | References | PDF (829.3 KB) | EPUB
  • 568 Views
  • 13 CrossRef citations
  • 0Altmetric

Review

Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
David M. Goldenberg & Robert M. Sharkey
Pages: 871-885
Published online: 12 May 2020
AbstractforSacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy | Full Text | References | PDF (1.4 MB) | EPUB
  • 4163 Views
  • 41 CrossRef citations
  • 0Altmetric
Cell therapy for type 1 diabetes
Cristian Loretelli, Emma Assi, Andy Joe Seelam, Moufida Ben Nasr & Paolo Fiorina
Pages: 887-897
Published online: 17 Apr 2020
AbstractforCell therapy for type 1 diabetes | Full Text | References | PDF (1 MB) | EPUB
  • 1347 Views
  • 13 CrossRef citations
  • 0Altmetric
Rituximab treatment of ANCA-associated vasculitis
Loïc Raffray & Loïc Guillevin
Pages: 899-910
Published online: 05 May 2020
AbstractforRituximab treatment of ANCA-associated vasculitis | Full Text | References | PDF (1.1 MB) | EPUB
  • 910 Views
  • 9 CrossRef citations
  • 0Altmetric
Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa
Allison R. Keith, Kirk Twaroski, Christen L. Ebens & Jakub Tolar
Pages: 911-923
Published online: 20 Mar 2020
AbstractforLeading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa | Full Text | References | PDF (1.6 MB) | EPUB
  • 368 Views
  • 14 CrossRef citations
  • 0Altmetric
A review of antibody-based therapeutics targeting G protein-coupled receptors: an update
Catherine J. Hutchings
Pages: 925-935
Published online: 08 Apr 2020
AbstractforA review of antibody-based therapeutics targeting G protein-coupled receptors: an update | Full Text | References | PDF (1.1 MB) | EPUB
  • 8442 Views
  • 29 CrossRef citations
  • 0Altmetric
Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy
Misako Matsumoto, Yohei Takeda & Tsukasa Seya
Pages: 937-946
Published online: 07 Apr 2020
AbstractforTargeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy | Full Text | References | PDF (1.1 MB) | EPUB
  • 391 Views
  • 17 CrossRef citations
  • 0Altmetric
CGRP pathway monoclonal antibodies for cluster headache
Calvin Chan & Peter J. Goadsby
Pages: 947-953
Published online: 28 Apr 2020
AbstractforCGRP pathway monoclonal antibodies for cluster headache | Full Text | References | PDF (790.5 KB) | EPUB
  • 950 Views
  • 12 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Understanding patient variability to biologic treatments in inflammatory bowel disease
Ahmad Z. Al Meslamani
Editorial | Published online: 26 May 2024
Free Access
Next-generation CD40 agonists for cancer immunotherapy
Hampus Andersson et al.
Review Article | Published online: 23 May 2024
Open Access
Non-TNF biologics and their biosimilars in rheumatoid arthritis
Tsz Ching Mok et al.
Review Article | Published online: 22 May 2024
Could siRNA therapeutics change the way we treat dyslipidemia?
Peter E. Penson et al.
Editorial | Published online: 22 May 2024
Free Access
View all latest articles